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sources. The NHS perspective was taken and included direct
costs only. In the decision analytical model, patients either
receive MAL-PDT or cryotherapy ﬁrst line with second line
therapy depending on lesion response. A one-year time horizon
was used to capture all relevant resource use and to assess the
clinical response. An excellent cosmetic outcome was deﬁned as
100% complete lesion response, but also no scarring, atrophy or
induration, and no or slight occurrence of redness or change in
pigmentation compared to adjacent skin. Key efﬁcacy data from
the clinical trial were subjected to a stochastic sensitivity analy-
sis using a Beta prior distribution and 1000 simulations.
RESULTS: From the deterministic model, the MAL-PDT strat-
egy dominated cryotherapy. Seventy-three percent of patients
had an excellent cosmetic outcome with MAL-PDT at a cost of
£832.93 per patient compared to 42% of cryotherapy patients
(£843.08 per patient). In the stochastic analysis using 1000 sim-
ulations, 95% of the ICERs were in the range -£161 to £191.
MAL-PDT was the dominant in strategy in 66.3% of the simu-
lations. CONCLUSIONS: MAL-PDT is at least as cost-effective
as cryotherapy in the treatment of thin or non-hyperkeratotic
actinic keratoses (AK) on the face or scalp and has superior cos-
metic outcomes.
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OBJECTIVE: To compare the annual costs of treatment incurred
by a health plan for patients diagnosed with actinic keratosis
(AK) and treated with ﬂuorouracil or cryosurgery. METHODS:
Pharmacy and medical claims from 2.7 million members of a
managed care organization in California, Oklahoma, Oregon,
Texas, and Washington, were examined. Adult patients newly
treated for AK with either 5% ﬂuorouracil cream or cryosurgery,
between January 1 and December 31, 2001, were identiﬁed.
Patients treated with cryosurgery were further stratiﬁed by
number of lesions (i.e., 1, 2–14, >15). Disease-related health care
costs (pharmacy and medical) for a 2-year follow-up period were
evaluated. RESULTS: Of the 9279 identiﬁed patients, 498
(5.4%) were treated with ﬂuorouracil and dermatologists pre-
scribed this medication (48.4%) more often than other special-
ties. Among the 8781 patients treated with cryosurgery, 3004
(34.2%), 5130 (58.4%), and 647 (7.4%) were identiﬁed with 1,
2–14, and >15 lesions, respectively. Total disease-related health
care costs during the follow-up period for the ﬂuorouracil cohort
averaged $509, compared to $296, $523, and $898 for the 1,
2–14, and >15 lesion cohorts, respectively. CONCLUSION: AK
is a common pre-malignant lesion that can develop into squa-
mous cell carcinoma. Numerous options are available for the
treatment of AK, all of which have been shown to be equally
efﬁcacious. In this study, use of 5% ﬂuorouracil cream for the
treatment of multiple AK lesions was cost saving compared to
cryosurgery. Similarly, because ﬂuorouracil is known to treat
sub-clinical lesions, additional savings may be realized for
periods longer than two years.
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The economic burden of psoriasis varies by disease severity.
Moderate to severe psoriasis requires use of systemic treatment
agents and is likely to be associated with higher medical costs.
OBJECTIVE: To estimate health care utilization rates and per-
patient costs for the treatment of moderate to severe psoriasis.
METHODS: A database of health insurance claims from 58 US
commercial health plans was used to obtain patient-level data.
Patients, aged 18–64, included in the analysis had a diagnosis of
psoriasis, and received >1 treatment cycle of at least one of the
following systemic agents: psoralen plus ultraviolet A (PUVA),
methotrexate (Mtx), cyclosporine, acitretin, etretinate, ultravio-
let B (UVB), and systemic corticosteroids (Cs). Patients with <6
months of observation period and those with rheumatoid arthri-
tis and other autoimmune diseases were excluded from the analy-
sis. RESULTS: A total of 1780 patients met all eligibility criteria
noted above (Group 1). Another 282 patients were newly diag-
nosed patients with no prior history of claims for psoriasis (New
Starts; Group 2). The most frequently used systemic therapies by
patients in Group 1, over a period of 1 year, were Cs (42%),
UVB (37%), PUVA (26%), and Mtx (22%). Of patients in
Group 2, 56%, 37%, 31%, and 18% received UVB, Cs, PUVA,
and Mtx. In an analysis of annual per-patient costs for drugs,
outpatient services, and inpatient services, results were compa-
rable for Groups 1 and 2. In Group 1, mean (median) annual
per-patient costs were $917 ($473), $199 ($85), and $6 ($0),
respectively and the corresponding costs for Group 2 were $744
($412), $179 ($63), and $0 ($0), respectively. 90th percentile
annual per-patient costs among all patients and New Starts were
$2932 and $2125, respectively. CONCLUSIONS: Estimates of
annual per-patient costs of treating moderate to severe psoriasis
exceed those reported previously, and reﬂect a considerable
direct medical burden.
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OBJECTIVE: To compare health care expenditures among
patients with dermatophytosis with different predisposing,
enabling and need factors as deﬁned by Andersen-Laake Behav-
ioral Model. METHODS: A cross-sectional analysis of the 1999
Medical Expenditure Panel Survey (MEPS) was conducted.
Patients with dermatophytosis aged 18 years and above were
included in the study. Health care expenditures included costs
related to prescription medications, outpatient, emergency room
and inpatient visits. Predisposing factors included age, gender,
race, education, and marital status. Enabling factors included
insurance type, employment status, family size and income. Need
factors included comorbid conditions, perceived mental and
health status. Analysis of covariance was used to compare the
levels of different factors affecting health care expenditures
adjusting for age. Sampling weights provided by MEPS were
used to provide representative estimates. RESULTS: A total of
156 patients with dermatophytosis were identiﬁed (ICD-9-CM
code = 110.x). These represented 1.8 million patients nationally.
The average age of patients was 51 years. The majority of the
respondents were female (52%); caucasian (87%) had private
insurance (80%) and was married (62%). Health care expendi-
tures for females was signiﬁcantly higher than for males ($831
vs. $450) (p = 0.03). Patients in families with less than three
members spent $232 more than those in families with three or
more members (p = 0.04). Patients with some college education
or higher had higher health care expenditures ($718) compared
with those who had attended high school ($581) or elementary
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grades ($272), however, the differences in expenditures were not
statistically signiﬁcant. No statistically signiﬁcant differences
were detected in the health care expenditures among categories
of other variables but this may be due partly to the relatively
small sample size. CONCLUSION: Gender and family size
appeared to play a role on the magnitude of health care expen-
ditures among dermatophytosis patients.
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OBJECTIVES: This study examined the relationship between
depressive symptoms and related medication adherence and
health care costs in older adults (age ≥ 65 years) with psoriasis.
METHODS: This was a prospective longitudinal cohort study
over a 2-year post enrollment period in a population of older
adults with psoriasis enrolled in a Medicare Health Maintenance
Organization (HMO) in southeastern United States with pre-
scription beneﬁts. Upon enrollment, each enrollee was mailed a
comprehensive health status assessment battery, which included
the Center for Epidemiologic Studies Depression (CES-D) scale.
Information on medication adherence (using medication posses-
sion ratio) and total health care utilization/costs following enroll-
ment were retrieved from the Medicare HMO database.
Sixty-three older adults with psoriasis using topical corticos-
teroids therapy and enrolled in the Medicare HMO for a 2 year
continuous period were included in the ﬁnal sample. RESULTS:
Nearly one-ﬁfths of the patient population had depressive symp-
toms. Patients with psoriasis who had depressive symptoms at
the time of enrollment were less likely to be adherent to topical
corticosteroid medication (Spearman rho = -0.29, p < 0.01) and
less likely to utilize health care resources as evidenced by lower
health care costs (Spearman rho = -0.27, p < 0.05), after con-
founder adjustment. CONCLUSIONS: The prevalence of
depressive symptoms in older adults with psoriasis is common-
place, with strong, yet unexplained correlations between pres-
ence of depressive symptoms and lower rates of medication and
health care service use among these patients.
EAR/EYE/SKIN DISEASES OR DISORDERS
EAR/EYE/SKIN DISEASES OR DISORDERS—Quality Of
Life Studies
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OBJECTIVES: To determine if the quality-of-life of AMD
patients with monocular visual dysfunction differs from that of
those with bilateral visual dysfunction. METHODS: A cross-
sectional study (n = 168) determined if there was a statistically
signiﬁcant difference in patient-reported health related quality-
of-life (HRQoL) of AMD patients with monocular versus 
bilateral visual dysfunction. Subjects underwent a series of 
interviewer-administered techniques to ascertain their HRQoL,
including the Visual Function Index (VF-14) and patient prefer-
ences elicited through both the time tradeoff (TTO) and stan-
dard reference gamble (SRG). Visual acuity obtained from a
subject’s better- and worse-seeing eye was categorized as 20/20
to 20/40, 20/40–20/70, 20/80–20/200, and worse than 20/200.
Based on the various combinations of these 4 visual acuity
groupings in the better-seeing (BSE) and worse-seeing eyes
(WSE), subjects were classiﬁed into one of 10 subgroups. Mul-
tivariate linear regression determined if an association existed
between various clinical variables and HRQoL. RESULTS: The
mean age was 72 years; 63% were females. Mean scores were:
VF-14, 66.1; TTO, 0.86; SRG, 0.89. Subjects with binocular
visual dysfunction reported a lower HRQoL compared to those
with monocular dysfunction (p < 0.001); mean differences in the
TTO, SRG, and VF-14 were 0.19 (SE = 0.04), 0.14 (SE = 0.04),
and 59.2 (SE = 3.9), respectively. Multivariate models demon-
strated that only visual acuity subgrouping, a function of acuity
in both the BSE and WSE, was associated with HRQoL score
(overall eta2 = 34.8%, p < 0.01, and partial eta2 equal to 22%
[TTO], 20% [SRG] and 60% [VF-14]). Models including both
BSE and WSE visual acuity explained an additional 10% in
HRQoL variability compared to models with only BSE visual
acuity. CONCLUSIONS: Subjects with binocular visual dys-
function reported a signiﬁcantly lower HRQoL as compared to
those with monocular dysfunction. These results suggest that
binocular vision is a better predictor of HRQoL in AMD than
only visual acuity in the BSE.
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OBJECTIVE: The lack of speciﬁc ICD-9 codes and under self-
reporting and diagnosis of ChHD suggests a need for a self-
assessment survey to identify ChHD. This pilot study was
conducted to validate a newly designed self-assessment ques-
tionnaire and the Skindex-29 QoL instrument for use by ChHD
patients. METHODS: A clinical questionnaire, consisting of 16
questions, was developed to identify patients with ChHD and to
assess its severity, through patient self-administration. Sensitiv-
ity, speciﬁcity, and receiver operating characteristic (ROC) curve
were used to evaluate how closely the ChHD diagnosis based on
self-assessment concurred with physician’s diagnoses. Also,
Skindex-29, a QoL instrument with 29 questions not previously
validated in a ChHD population, was evaluated for internal con-
sistency and construct validity for ChHD patients in this study.
Forty-patients (ChHD n = 20; other skin disorders n = 20), with
a mean age of 46.6 ± 14.8 years and 30% males, were randomly
selected from a dermatology clinic in Louisville, Kentucky for
this pilot study. RESULTS: The performance of the clinical ques-
tionnaire matched the physicians’ diagnosis in identifying ChHD
with a sensitivity of 85%, a speciﬁcity of 95%, and an area under
the ROC curve of 0.83. The internal consistency of the Skindex-
29 was higher than that reported previously in a general der-
matology population, with a Cronbach alpha of 0.77 to 0.94 for
3 different (symptoms, emotions and functioning) domains. The
construct validity of Skindex-29 was evaluated by examining the
correlation between the overall score and physician’s assessment
of ChHD severity. The Pearson rho was 0.55 (p = 0.07), slightly
lower than that reported previously, but higher than that
reported for other QoL instruments. CONCLUSIONS: This
study indicates that the newly developed ChHD self-assessment
